Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 11 Show results per page	View Search Criteria \| Help With Results


1.		A Prospective,Multi-Center,Randomized Control Trial of Preoperative Hepatic and Regional Arterial Chemotherapy(PHRAC) to Prevent Postoperative Liver Metastasis of Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Approved-not yet active				18 to 74				Other				2008-46 no, NCT00643877


2.		Intraperitoneal Floxuridine in Gastric Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Not specified				Other				2150 NCT00058916

Last Modified: 12/7/2006 First Published: 12/2/2005


3.		Phase II Randomized Study of Hepatic Arterial Infusion Comprising Floxuridine and Dexamethasone and Systemic Combination Chemotherapy With or Without Bevacizumab in Patients With Completely Resected Hepatic Metastases From Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				MSKCC-04086 NCT00200200

Last Modified: 8/26/2008 First Published: 12/1/2006


4.		Phase II Study of Chemotherapy and Selective Internal Radiation Therapy Comprising Yttrium Y 90 Resin Microspheres in Patients With Colorectal Cancer Metastatic to the Liver

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				CCCGHS-CHEMO-SIRT NCT00408551

Last Modified: 4/10/2008 First Published: 12/8/2006


5.		Phase II Study of Hepatic Arterial Infusion Comprising Floxuridine and Dexamethasone in Combination With Systemic Bevacizumab in Patients With Unresectable Primary Hepatic Malignancy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Diagnostic, Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				MSKCC-06114 GENENTECH-MSKCC-06114, NCT00410956

Last Modified: 5/23/2007 First Published: 3/14/2007


6.		Phase II Study of Irinotecan Hydrochloride, Floxuridine, Leucovorin Calcium, and Bevacizumab in Patients With Stage IV Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other, Pharmaceutical / Industry				SCCC-2005145 EPROST-20060252, SCCC-20060252, SCCC-20060042, PFIZER-SCCC-2005145, NCT00449163

First Published: 3/14/2007


7.		Phase II Study of Floxuridine, Leucovorin Calcium, Oxaliplatin, and Docetaxel as First-Line Treatment in Patients With Unresectable Stage IV Gastric Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other, Pharmaceutical / Industry				SCCC-2003150 EPROST-20040005, SCCC-20050983, AVENTIS-SCCC-2003150, SCCC-20040005, NCT00448682

Last Modified: 6/10/2008 First Published: 6/21/2007


8.		Phase II Study of Hepatic Arterial Infusion Comprising Floxuridine and Dexamethasone in Combination With Systemic Irinotecan Hydrochloride, Leucovorin Calcium, Oxaliplatin or Fluorouracil, and Bevacizumab in Patients With Initially Unresectable Colorectal Cancer Metastatic to the Liver

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				MSKCC-06075 06-075 A(2), NCT00492999

Last Modified: 12/26/2007 First Published: 4/23/2003


9.		Phase I Adjuvant Study of Hepatic Arterial Infusion of Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Patients With Resectable Hepatic Metastases Secondary to Colorectal Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI				MSKCC-03005 NCT00059930


10.		Safety Study of Oxaliplatin and 5-Fluorouracil Followed by FUDR for Unresectable Colorectal Liver Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 to 80				NCI, Other				05-096 NCT00557557

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute